What do systematic reviews say?

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

CCPT vs AD

The review found no eligible studies for this question.

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CCPT vs exercise

The review found no eligible studies for this question.

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Deferasirox vs deferiprone (DFO)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFX film‐coated tablet vs DFX dispersible tablet

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs DFP

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs deferoxamine

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs DFP and DFX

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  GRADE not reported

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

VAL‐1221 vs alglucosidase alfa

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 41 participants
  Very low

High‐dose rhGH vs standard‐dose rhGH

The review found no eligible studies for this question.

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Summary of findings: garlic supplementation vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: nitric oxide vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Zinc vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: β‐carotene vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Very low